For Investors and Business Development Teams
Diligence, Portfolio Support, and Preclinical Leadership for Your Pipeline
Independent preclinical assessments, hands-on portfolio company support, and embedded preclinical leadership. From rapid screens to fractional Head of Preclinical, we help you evaluate, build, and de-risk your pipeline.
Complimentary. Discuss your diligence or portfolio needs.
Diligence That Moves at the Pace of Deal Flow
Every memo opens with a clear go/watch/pass recommendation. No hedging, no consultant-speak, no 30-page reports that avoid a conclusion. You get a decision framework, not a literature review.
Our founder has been on both sides of the table, building IND-enabling preclinical programs inside biotech companies and evaluating assets for licensing and acquisition at Sarepta Therapeutics, supporting diligence on transactions up to $11B.
How Diligence Engagements Work
A simple workflow designed for active deal timelines.
1. Share the Opportunity
Tell us about the target asset, the decision question, and your timeline. We’ll recommend the right format.
2. Independent Assessment
We evaluate the preclinical program: mechanism, data quality, translational feasibility, competitive positioning, and key risks.
3. Decision Memo
Clear go/watch/pass recommendation with risk-ranked follow-ups and management diligence questions. Ready for your investment committee.
What Makes This Different
Most diligence consultants are academics who review literature. Our founder has actually built and evaluated programs from both sides of the table.
Speed
Rapid screens in 48 hours. Standard memos in 2-3 weeks. You get a clear recommendation while the deal is still live.
The Acquirer’s Lens
Pattern recognition from evaluating a high volume of assets across advanced modalities. We know what differentiates programs that survive diligence from those that don’t.
Signal Quality
Every memo opens with a clear go/watch/pass recommendation. No hedging. Actionable insights your investment committee can use directly.
Portfolio Company Support
When diligence uncovers gaps, BridgeLine builds the diligence-ready development plans your portfolio companies should already have. The Preclinical Roadmap is our signature engagement: a study-by-study plan from discovery through IND-enabling.
Strategy Diagnostic
The entry point: a multidimensional assessment of a portfolio company’s preclinical program with prioritized recommendations. 100% credit toward the Preclinical Roadmap.
Preclinical Roadmap
Our signature engagement: a diligence-ready, study-by-study development plan from discovery through IND-enabling with timelines, CRO shortlists, budgets, and biomarker strategy.
Fractional Head of Preclinical Strategy
Embedded senior leadership for portfolio companies needing preclinical strategy, CRO oversight, and milestone governance.
Diligence Services
Structured assessments designed for the pace of deal flow.
Rapid Screen
48-hour go/watch/pass assessment. 2-3 page memo covering scientific rationale, preclinical data quality, key risks, competitive positioning, and recommendation. For VCs screening 20-50 opportunities.
Standard Diligence Memo
Full preclinical program assessment with competitive positioning, go/watch/pass recommendation, and key questions for management. Delivered in 2-3 weeks.
Deep-Dive Diligence Memo
Expanded mechanism, translational risk, competitive analysis, and regulatory pathway assessment for high-conviction opportunities.
Diligence-on-Demand Retainer
Priority access for active deal flow. 5-business-day SLA on memos, one rapid screen per month included. For firms with continuous pipeline assessment needs.
What’s in a Diligence Memo
Every memo opens with an executive summary and a clear recommendation.
Standard Diligence Memo
Deep-Dive Diligence Memo
Everything in the standard memo, plus expanded analysis for high-conviction opportunities:
Modality Coverage
Gene Therapy
Gene Editing, Non-Viral
RNA Therapeutics
ASO, siRNA, mRNA, miRNA
Biologics
Protein Therapeutics, Antibodies
Scope Clarity
What this support covers and what it does not.
In Scope
- Scientific and translational risk assessment
- Go/watch/pass framing and decision memos
- Management Q&A preparation for diligence calls
- Competitive evidence and differentiation framing
- Portfolio company preclinical support
Out of Scope
- Legal diligence or legal opinion
- Financial valuation model construction
- Direct investment or transaction advisory
- Primary experimental execution
Need a Diligence Memo This Week?
Book a Strategy Call. We’ll discuss your deal flow, assessment needs, and how BridgeLine can support your diligence process.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com